Support for Veterans with lung cancer.
Official title: Engagement of Veterans With Lung Cancer (EVLC)
Run by Palo Alto Veterans Institute for Research · NCT07219251 · Data updated 2026-11-12
This study will test whether weekly phone support from a trained lay health worker can improve quality of life for Veterans who are newly diagnosed with lung cancer or who finished treatment within the past year.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 194 (estimated) |
| Sponsor | Palo Alto Veterans Institute for Research Academic / other |
| Drugs / interventions | chemotherapy, immunotherapy, radiation |
| Locations | 1 site (Palo Alto, California) |
| Status | Recruiting |
| Started | February 27, 2026 |
| Main results expected | December 31, 2030 |
| Study ends | December 31, 2032 |
| Registry record updated | March 3, 2026 |
| Trial ID | NCT07219251 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Veterans aged 18 or older with a diagnosis of any-stage lung cancer who speak English or Spanish, can complete questionnaires, have a valid phone number, receive oncology care at a participating site, and are newly diagnosed or treated within the past 12 months are ideal candidates.
✕Probably not a fit
Patients lacking capacity to consent, those actively receiving hospice care, or Veterans not receiving oncology care at the participating VA site (or without a phone or ability to complete questionnaires in English or Spanish) are unlikely to benefit from this intervention.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This randomized study will enroll 194 Veterans with any stage of lung cancer and assign them 1:1 to usual oncology care or usual care plus weekly telephone contact with a trained lay health worker for six months. The lay health worker will provide education, symptom-management support, help with healthcare planning, and discussions about care preferences and goals. The primary outcome is health-related quality of life; secondary outcomes include acute care use, patient activation, anxiety and depression, documentation of goals of care, and use of palliative or hospice services. Outcomes for the intervention group will be compared to usual care using participant-reported surveys and clinical records over the follow-up period.
Why it matters
Potential benefit: If successful, the intervention could improve patient quality of life and reduce emergency or hospital visits by helping Veterans manage symptoms and clarify care goals.
How similar studies have gone: Previous lay health worker and patient-navigation programs in oncology have shown mixed but generally encouraging effects on symptom management and care engagement, though direct evidence in Veterans with lung cancer is limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Veteran patients with diagnosis of any stage of lung cancer; 2. 18 years of age or older; 3. English- or Spanish-speaking; 4. can self-administer questionnaires in English or Spanish; 5. valid telephone number; 6. receiving oncology care at participating sites; 7. currently newly diagnosed or receiving or having completed systemic anti-cancer therapy and/or radiation therapy within 12 months, defined as oral, injection, or intravenous therapy (chemotherapy, targeted therapy, or immunotherapy) Exclusion Criteria: 1. no capacity to consent; 2. actively receiving hospice care
Where it's running
-
Veterans Affairs Palo Alto Health Care System (VAPAHCS)
Palo Alto, California, United States Recruiting
Study contacts
- Study coordinator: Manali I Patel, MD MPH MS
- Email: manalip@stanford.edu
- Phone: 6504935000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ivonescimab alone or with carboplatin/pemetrexed for advanced NSCLC with actionable alterations
This trial tests if ivonescimab, alone or with chemotherapy, can shrink tumors in advanced NSCLC patients who have actionable genomic alterations after prior targeted therapies.
-
SL-28 for Advanced Solid Tumours
A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.
-
Using liquid biopsy from EBUS-TBNA fluid to diagnose lung cancer
This study is testing if analyzing fluid from a specific lung procedure can help diagnose lung cancer in patients who are suspected to have it but have had negative test results.
-
Comparing standard care to early palliative care for advanced lung cancer patients
This study tests if adding early palliative care to standard treatment can help improve the quality of life and survival for people with advanced lung cancer.
-
Treatment of advanced lung cancer using KB707
This study is testing a new treatment called KB707 to see if it can help adults with advanced lung cancer by boosting their immune response, especially for those who haven't had success with standard therapies.
-
Integrated genomic and clinical database for cancer biomarker discovery
Researchers are building a combined genomic and clinical database at Samsung Medical Center to test biomarkers for cancer diagnosis, treatment choice, and predicting how well treatments work.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.